First event: March 24th and 25th (Two-day symposium)
Hosted by National Institute of Allergy and Infectious Disease
"Moving from Hepatitis Discovery to Elimination: NIH Research Advancing Hepatitis Elimination" will kick off in 2022 with a deep-dive symposium on the latest research related to HCV vaccine development, hosted by the National Institute of Allergy and Infectious Diseases (NIAID). Over two days- March 24th and 25th- eight speakers will discuss results from clinical trials for past candidate vaccines, new findings in HCV immunology and implications for vaccine development, and emerging vaccine platforms, such as mRNA, that could be applied to HCV. Nobel Laureate, Dr. Michael Houghton, will close the symposium with his thoughts on the opportunity of HCV vaccine development within the next decade.
Plenary I. Thursday March 24; 12.00 – 14.30 ET
-David Thomas, Johns Hopkins University
"The possibility and urgency of a hepatitis C vaccine"
-Andrea Cox, Johns Hopkins University
"Factors that limited vaccine efficacy in the first prophylactic HCV vaccine trial"
-Arash Grakoui, Emory University
"Protective immunity to HCV during natural reinfection and the development of vaccine modalities"
-Thomas Fuerst, University of Maryland
"Structure-guided comparison of secreted vs membrane-bound forms of HCV E1E2 vaccine candidates and delivery considerations"
Plenary II. Friday March 25; 12.00 – 14.30 ET
-Mansun Law, The Scripps Research Institute
"Next Generation HCV Vaccine Antigens: What we know about HCV neutralizing antibody responses & how to leverage recent knowledge in vaccine design"
-Justin Bailey, Johns Hopkins University
"HCV vaccines and neutralizing antibodies: lessons from human infection"
-Bali Pulendran, Stanford University
"Systems biological assessment of immune responses to the Pfizer BioNTech BNT162b2 mRNA vaccine: lessons for HCV"
-Michael Houghton, University of Alberta
"Feasibility of delivering a HCV vaccine by the end of this decade"